WASHINGTON (AP) — Health advisers on Friday unanimously backed the full approval of a closely watched Alzheimer’s drug, a key step toward opening insurance coverage to U.S. seniors with early stages of the brain-robbing disease. The drug, Leqembi, received conditional approval from the Food and Drug Administration in January based…Read More
Alzheimers drug gets FDA panels backing setting the stage for broader use
